Categories
Uncategorized

Study Guide: Epidemiology of Adult Obesity (Chapter 2)

I. Defining Obesity as a Chronic Disease

Obesity is recognized as a complex chronic disease. It is characterized by abnormal or excess body fat (adiposity) that impairs health, increases the risk of long-term medical complications, and reduces lifespan.

Key Measurements and Classifications

  • Body Mass Index (BMI): Calculated as weight (kg) divided by height squared ().

    • Overweight: BMI .

    • Obesity: .

    • Class I: BMI .

    • Class II: BMI .

    • Class III: .

    • Severe Obesity: Defined as a (includes Class II and III).

  • Waist Circumference (WC): A proxy for abdominal adiposity. Thresholds for increased health risk:

    • Men: (40 inches).

    • Women: (35 inches).

  • Edmonton Obesity Staging System (EOSS): A five-point system (0–4) that examines comorbidity and functional status. It predicts mortality independent of BMI and is a valuable clinical screening tool.

II. Canadian Epidemiological Trends

The prevalence of obesity in Canada has risen dramatically over the last 30 years.

  • Three-fold Increase: Since 1985, the prevalence of adult obesity has increased by 300%.

  • Current Impact: In 2016, obesity affected 26.4% (8.3 million) of Canadian adults.

  • Severe Obesity Growth: This is the fastest-growing subgroup, increasing 455% since 1985.

  • Abdominal Obesity: Measures of waist circumference are increasing more pronouncedly than BMI trends, which is concerning because it is associated with higher health risks.

  • Regional Variation: Obesity prevalence is highest in the Atlantic Provinces and lowest in British Columbia and Quebec.

III. Health Consequences and Risks

Obesity reduces life expectancy by 6 to 14 years.

1. Medical Complications

  • Cardiovascular: Increased risk of heart disease, stroke, and hypertension.

  • Metabolic: Higher risk of Type 2 diabetes, non-alcoholic fatty liver disease, gallbladder disease, and gout.

  • Cancer: Roughly 20% of all cancers are attributed to obesity. It specifically increases the risk of colon, kidney, pancreatic, post-menopausal breast, and endometrial cancers.

  • Mechanical: A nearly three-fold increase in the risk of osteoarthritis and impaired mobility.

2. Psychosocial and Mental Health

  • Individuals with obesity are twice as likely to be diagnosed with a mood disorder.

  • Weight bias, stigma, and discrimination are pervasive in the healthcare system, leading to health inequalities and avoidance of care.

IV. Complex Causes and Contributors

Obesity is not simply a matter of individual choice or “calories in vs. calories out”.

  • Environmental & Energy Balance: While calorie intake has decreased and leisure physical activity has increased in Canada, other factors promote weight gain. These include chronic stress, insufficient sleep, and “energy-saving conveniences” (cars, remotes).

  • Iatrogenic Factors: Many medications used to treat obesity-related comorbidities (depression, hypertension, diabetes) actually promote weight gain.

  • Socio-Cultural Factors: * Indigenous Populations: On-reserve First Nations adults report higher obesity rates (36%) than Inuit or Métis populations.

    • Income & Sex: Income and education are inversely associated with obesity in women, but income shows a positive relationship with obesity in men.

    • Ethnicity: South Asian and Chinese populations have lower obesity rates than white populations, but they face increased cardiometabolic risk at lower BMIs.

Clinical Pearl: Do not rely solely on BMI to predict health risk. Some individuals with elevated BMI are “metabolically healthy,” while others with lower BMIs (particularly in certain ethnic groups) may be at high risk.


Reference: 

Twells LK, Janssen I, Kuk JL. Canadian Adult Obesity Clinical Practice Guidelines: Epidemiology of Adult Obesity. August 4, 2020. Accessed August 4, 2020. https://obesitycanada.ca/epidemiology/
Categories
CDE Diabetes Uncategorized

Practice Exam: Pharmacologic Glycemic Management (2024 Update)

You have reviewed the study guide for the Diabetes Canada 2024 Pharmacologic Update, and now it is time to test your knowledge.

This is arguably the most critical section of the CDE exam. The 2024 Guidelines have cemented a paradigm shift in diabetes care: we are no longer treating “sugar” in isolation; we are treating risk. The exam will require you to look beyond the A1C number and identify patients who need Cardiorenal Protection regardless of their glycemic control.

What to expect in this quiz: This practice exam focuses on the complex decision trees introduced in the latest update. You will be tested on:

  • The “Cardiorenal Path”: Identifying patients with ASCVD, Heart Failure, or CKD who require an SGLT2 inhibitor or GLP-1 RA, even if their A1C is already at target.

  • The “1.5% Rule”: Knowing when to bypass monotherapy and initiate Metformin + a second agent immediately at diagnosis.

  • Symptomatic Decompensation: Recognizing the clinical signs (weight loss, severe hyperglycemia) that mandate the immediate start of Insulin.

  • Heart Failure Nuances: Specifically recalling that SGLT2 inhibitors are the only class proven to reduce hospitalizations for heart failure.

1. According to the guidelines, what is the timeframe goal for reaching target A1C after dose adjustments or additions of medications?

2. Case: A patient using a GLP1-RA is scheduled for elective surgery. According to the User’s Guide, what is the concern?

3. Case: A patient with type 2 diabetes and chronic kidney disease (CKD) needs intensification of therapy. According to the guidelines, which SGLT2 inhibitors have demonstrated evidence of benefit for CKD?

4. According to the guidelines, which SGLT2 inhibitors have demonstrated reduction in MACE outcomes in people at high CV risk?

5. According to the 2024 guidelines, what is the recommended first-line antihyperglycemic medication for most people with type 2 diabetes who require pharmacotherapy?

6. According to the guidelines and User’s Guide, why should GLP1-RAs NOT be used together with DPP4 inhibitors?

7. What is the recommended target dose of metformin when initiating therapy?

8. Case: A patient is concerned about the risk of DKA with SGLT2 inhibitors. According to the User’s Guide, when should SGLT2 inhibitors be held?

9. Case: A diabetes educator is evaluating a patient with type 2 diabetes who is not meeting glycemic targets. Before intensifying pharmacologic therapy, what should be assessed according to the guidelines?

10. According to the guidelines, what are the benefits of adding insulin to non-insulin antihyperglycemic agents compared to using insulin alone?

11. Case: A patient with type 2 diabetes has GI intolerance to immediate-release metformin. According to the User’s Guide, what strategies can be used?

12. According to the User’s Guide, what is the dose-response relationship for SGLT2 inhibitors regarding glucose lowering and cardiorenal benefits?

13. Case: A diabetes educator is discussing NPH insulin with a patient. According to the User’s Guide, what is a major challenge with NPH insulin?

14. According to the guidelines, what is the recommended approach for initiating bolus insulin in type 2 diabetes?

15. According to the evidence, what is the effect on A1C when combining metformin with another agent at the outset compared to metformin alone?

16. According to the guidelines, when should insulin be initiated immediately with or without metformin?

17. According to the evidence comparing metformin with other agents as monotherapy, what are the relative advantages of metformin?

18. What is the typical A1C reduction with non-insulin antihyperglycemic agent monotherapy?

19. Case: A patient with type 2 diabetes develops heart failure with reduced ejection fraction (HFrEF). According to the guidelines, which medication class should be prioritized?

20. Case: A patient with type 2 diabetes experiences declining kidney function. According to the guidelines, at what eGFR level is metformin contraindicated?

21. Which drug class is associated with negligible risk for hypoglycemia and leads to weight loss?

22. According to the User’s Guide, what is the concern with using oral semaglutide compared to subcutaneous semaglutide?

23. Case: A healthcare team is considering using a TZD for a patient. According to the User’s Guide, what potential benefits and risks should be considered?

24. According to the guidelines, what should be done when bolus insulin is introduced into a treatment regimen?

25. According to the UKPDS, what was demonstrated with metformin monotherapy in newly-diagnosed participants who had overweight?

26. Which GLP1-RAs have demonstrated reduction in major adverse cardiovascular events (MACE) in people at high CV risk?

27. Case: A 58-year-old patient with newly diagnosed type 2 diabetes has an A1C of 9.5% (target 7.0%). According to the guidelines, what is the recommended initial pharmacotherapy approach?

28. What is the recommended starting dose of metformin to minimize gastrointestinal side effects?

29. Case: A patient asks about tirzepatide compared to GLP1-RAs. According to the User’s Guide, what does the evidence show?

30. Case: A patient with type 2 diabetes and heart failure with preserved ejection fraction (HFpEF) needs therapy intensification. Which medications have demonstrated benefit?

31. Case: A diabetes educator is counselling a patient about sulfonylureas. What are the key concerns with this drug class?

32. According to the evidence, what is the A1C threshold above target where combination therapy is recommended as initial pharmacologic therapy?

33. According to the guidelines, which long-acting basal insulin analogues may be considered to reduce the risk of nocturnal hypoglycemia?

34. Case: A patient asks whether using both a GLP1-RA and SGLT2 inhibitor together will provide additional cardiorenal benefit. What does the evidence show?

35. According to the guidelines, what is the level of evidence supporting the use of basal-bolus injection therapy or CSII for cardiorenal protection in type 2 diabetes?


 

Categories
CDE Diabetes Uncategorized

Flashcards: Nutrition Therapy (Chapter 11)

Test your recall on the dietary strategies that drive diabetes management.

Nutrition therapy is a fundamental pillar of diabetes care, capable of lowering A1C by up to 2.0%. These flashcards are designed to help pharmacists and healthcare professionals quickly review the evidence-based recommendations for macronutrient distribution, dietary patterns, and specific food choices that improve metabolic outcomes.

Key Topics Covered:

  • Macronutrient Ranges: Memorizing the flexible distribution ranges for carbohydrates (45–60%), protein (15–20%), and fat (20–35%).

  • Dietary Patterns: Identifying specific benefits of Mediterranean, DASH, Vegetarian, and Portfolio diets for glycemic control and cardiovascular health.

  • Carbohydrate Quality: Understanding the role of Glycemic Index (GI) and the recommended daily target for dietary fibre (30–50 g).

  • Fat & Sugar Limits: Recalling the specific thresholds for saturated fat intake (<9% of total energy) and added sugars (<10% of total energy).

  • Clinical Considerations: Reviewing guidelines for alcohol consumption, non-nutritive sweeteners, and vitamin supplementation.